In our previous grant period (Neurovascular Protection for Subarachnoid Hemorrhage, NIH/NS053407 2007- 2011) we have studied endothelial protective mechanisms against cerebral vasospasm and brain edema. Our studies were the pioneering observations that early brain injury which is featured by an elevated intracranial pressure, reduced cerebral blood flow, decreased cerebral perfusion pressure, disrupted blood-brain barrier, increased brain edema, sporadically distributed neuronal cell death/apoptosis, and therefore resulted poor neurological functional evaluations within 72 hrs after SAH, is a determination factor, rather than cerebral vasospasm as we believed previously, for clinical outcome. Our observations lead the changes of the directions of SAH research, and most labs in the world are now studying early brain injury management to improve outcomes. During our previous studies, we have identified several promising candidates for neurovascular protection after subarachnoid hemorrhage (SAH) and one of them is osteopontin (OPN). OPN is an extracellular matrix protein that can interact with cell surface integrin receptors through its arginine-glycine- aspartate (RGD) sequence and has been implicated in promoting cell survival, proliferation and reducing cellular apoptosis. Recent studies from our laboratory and others have demonstrated the neurovascular protective effects of intracerebroventricular administration of recombinant osteopontin (rOPN) in various preclinical stroke models. However, the mechanism by which rOPN elicits neurovascular protection has not been evaluated. Elucidating the molecular mechanisms by which OPN exerts its effects would facilitate the development of a novel therapy to protect against SAH. Furthermore, we propose to administer rOPN intranasally, which is an established, safe, and non-invasive method to bypass the blood-brain barrier. The specific objective of this proposal is to determine the neurovascular protective potential of rOPN administered intranasally as a novel treatment strategy to reduce early brain injury after SAH, and to determine the mechanism of neurovascular protection conferred by rOPN through anti-apoptotic signaling and BBB stabilization. Our central hypothesis is that intranasal administration of rOPN provides protection against early brain injury after SAH by reducing neuronal apoptosis and stabilization of the BBB via integrin receptor signaling pathway. The following three specific aims are proposed to address our hypothesis.
Aim 1 will determine the neurovascular protective effect of intranasal rOPN administration after SAH. Our specific hypothesis is (1) that OPN concentration in CSF/brain will be increased after intranasal rOPN administration. (2) intranasal rOPN will improve neurological outcomes and reduce mortality after SAH via integrin receptor signaling.
Aim 2 will determine the mechanism of anti-apoptotic effect of rOPN after SAH. Our specific hypothesis is that (1) rOPN performs anti-apoptotic signaling mediated by FAK signaling and (2) via PI3K/ Akt pathways.
Aim 3 will determine the mechanism of blood brain barrier protection by rOPN after SAH. Our specific hypothesis is that rOPN protects BBB via ILK and Rac-1 pathways. The long-term goal of this proposal is to provide a basis for clinical translation of rOPN as an effective therapeutic option o protect against complications in patients after SAH and to improve overall patient outcomes in the long-term.

Public Health Relevance

Osteopontin is a protein that its level increased upon brain injury and protects brain cells. This project intends to establish a clinical relevant intranasal-dop in the nose-application of osteopontin and test its brain protective effect and mechanisms.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01NS081740-02
Application #
8661326
Study Section
Neural Oxidative Metabolism and Death Study Section (NOMD)
Program Officer
Koenig, James I
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Loma Linda University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
City
Loma Linda
State
CA
Country
United States
Zip Code
92354
Fujii, Mutsumi; Sherchan, Prativa; Soejima, Yoshiteru et al. (2014) Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats. Exp Neurol 261:396-403
Chen, Sheng; Li, Qian; Wu, Haijian et al. (2014) The harmful effects of subarachnoid hemorrhage on extracerebral organs. Biomed Res Int 2014:858496
Krafft, Paul R; McBride, Devin W; Lekic, Tim et al. (2014) Correlation between subacute sensorimotor deficits and brain edema in two mouse models of intracerebral hemorrhage. Behav Brain Res 264:151-60
Li, Qian; Khatibi, Nikan; Zhang, John H (2014) Vascular neural network: the importance of vein drainage in stroke. Transl Stroke Res 5:163-6
Manaenko, Anatol; Lekic, Tim; Barnhart, Margaret et al. (2014) Inhibition of transforming growth factor-? attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage. Stroke 45:828-34
Altay, Orhan; Suzuki, Hidenori; Hasegawa, Yu et al. (2014) Isoflurane on brain inflammation. Neurobiol Dis 62:365-71
Fujii, Mutsumi; Sherchan, Prativa; Krafft, Paul R et al. (2014) Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. J Neurol Sci 342:101-6
Zhang, John H (2014) Vascular neural network in subarachnoid hemorrhage. Transl Stroke Res 5:423-8
Liu, Fei; Hu, Qin; Li, Bo et al. (2014) Recombinant milk fat globule-EGF factor-8 reduces oxidative stress via integrin ?3/nuclear factor erythroid 2-related factor 2/heme oxygenase pathway in subarachnoid hemorrhage rats. Stroke 45:3691-7
Chen, Sheng; Feng, Hua; Sherchan, Prativa et al. (2014) Controversies and evolving new mechanisms in subarachnoid hemorrhage. Prog Neurobiol 115:64-91

Showing the most recent 10 out of 16 publications